<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutations in codons 12 or 13 of the first exon of the N-<z:mp ids='MP_0011356'>RAS</z:mp> gene have been reported in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in frequencies that vary between 9% and 40% depending on the techniques used in analysis </plain></SENT>
<SENT sid="1" pm="."><plain>Gene amplification and direct sequencing provides the only unambiguous method of detecting those mutations that induce amino acid alterations </plain></SENT>
<SENT sid="2" pm="."><plain>Using this technique, we analyzed 21 MDS patients for mutations in exon-1 of N-<z:mp ids='MP_0011356'>RAS</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Codon 12 mutations substituting aspartic acid (GAT) for glycine (GGT) were found in four cases, and a codon 13 mutation substituting alanine (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GCT</z:e>) for glycine (GGT) was detected in one patient </plain></SENT>
<SENT sid="4" pm="."><plain>We conclude that N-<z:mp ids='MP_0011356'>RAS</z:mp> exon-1 mutations in one patient </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that N-<z:mp ids='MP_0011356'>RAS</z:mp> exon-1 mutations producing amino acid changes occur in about 20% to 25% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases </plain></SENT>
</text></document>